It has also been hypothesized that while BCR-ABL1 expression is high in pre-therapy CD34+ cells, TKIs select for CML precursors with low BCR-ABL1 expression and signaling, hence less oncogene-addicted [161,162]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.